Viking Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire•03/11/2026•16:30 ET
0
Key Highlights
- ➤Viking Therapeutics (VKTX) will participate in five healthcare investor conferences
- ➤VK2735 is in Phase 3 studies for obesity in subcutaneous and oral formulations
- ➤VK2735 maintenance dosing strategies target long-term weight management
- ➤Fireside chats scheduled at Stifel, UBS, Jefferies, and Piper Sandler conferences
Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference in November and December.
Get started
Create a free account to read the full story.